Abstract
TDD with programmable intrathecal drug delivery systems (IDDS) has been approved for malignant and chronic nonmalignant pain treatment since 1991 and severe spasticity since 1992. Identification of rare product performance events within IDDS becomes possible with expanded clinical use, necessitating product modifications to mitigate patient risk. Presented here is real-world evaluation of product performance updated with the most recent data following release of an enhanced IDDS.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Neuromodulation: Technology at the Neural Interface
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
